Effects of tyrosine kinase inhibitor-masitinib mesylate on canine mammary tumour cell lines

1Battistello E., Katanayeva N., Dheilly E., Tavernari D., Donaldson M.C., Bonsignore, L., Thome M., Christie A.L., Murakami M.A., Michielin O., Ciriello, G., Zoete V., Oricchio E.: Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma. Blood 2018, 131, 2345–2356, doi: 10.1182/blood-2017-10-809210. Battistello E. Katanayeva N. Dheilly E. Tavernari D. Donaldson M.C. Bonsignore L. Thome M. Christie A.L. Murakami M.A. Michielin O. Ciriello G. Zoete V. Oricchio E. Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma Blood 2018 131 2345 2356 10.1182/blood-2017-10-809210596937729567799Open DOISearch in Google Scholar

2Bavcar S., Argyle D.J.: Receptor tyrosine kinase inhibitors: molecularly targeted drugs for veterinary cancer therapy. Vet Comp Oncol 2012, 10, 163–173, doi: 10.1111/j.1476-5829.2012.00342.x. Bavcar S. Argyle D.J. Receptor tyrosine kinase inhibitors: molecularly targeted drugs for veterinary cancer therapy Vet Comp Oncol 2012 10 163 173 10.1111/j.1476-5829.2012.00342.x22882485Open DOISearch in Google Scholar

3Chang C.Y., Chiou P.P., Chen W.J., Li Y.H., Yiu J.C., Cheng Y.H., Chen S.D., Lin C.T., Lai Y.S.: Assessment of the tumorigenesis and drug susceptibility of three new canine mammary tumor cell lines. Res Vet Sci 2010, 88, 285–293, doi: 10.1016/j.rvsc.2009.08.006. Chang C.Y. Chiou P.P. Chen W.J. Li Y.H. Yiu J.C. Cheng Y.H. Chen S.D. Lin C.T. Lai Y.S. Assessment of the tumorigenesis and drug susceptibility of three new canine mammary tumor cell lines Res Vet Sci 2010 88 285 293 10.1016/j.rvsc.2009.08.00619748110Open DOISearch in Google Scholar

4Ciardiello F., Tortora G.: A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001, 7, 2958–2970. Ciardiello F. Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor Clin Cancer Res 2001 7 2958 2970Search in Google Scholar

5Dubreuil P., Letard S., Ciufolini M., Gros L., Humbert M., Castéran N., Borge L., Hajem B., Lermet A., Sippl W., Voisset E., Arock M., Auclair C., Leventhal P.S., Mansfield C.D., Moussy A., Hermine O.: Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PloS One 2009, 4, e7258, doi: 10.1371/journal.pone.0007258. Dubreuil P. Letard S. Ciufolini M. Gros L. Humbert M. Castéran N. Borge L. Hajem B. Lermet A. Sippl W. Voisset E. Arock M. Auclair C. Leventhal P.S. Mansfield C.D. Moussy A. Hermine O. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT PloS One 2009 4 e7258 10.1371/journal.pone.0007258274628119789626Open DOISearch in Google Scholar

6Fahey C.E., Milner R.J., Kow K., Bacon N.J., Salute M.E.: Apoptotic effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine osteosarcoma cells. Anti-Cancer Drugs 2013, 24, 519–526, doi: 10.1097/CAD.0b013e32836002ba. Fahey C.E. Milner R.J. Kow K. Bacon N.J. Salute M.E. Apoptotic effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine osteosarcoma cells Anti-Cancer Drugs 2013 24 519 526 10.1097/CAD.0b013e32836002ba23466652Open DOISearch in Google Scholar

7Hahn K.A., Oglivie G., Rusk T., Devauchelle P., Leblanc A., Legendre A., Powers B., Leventhal P.S., Kinet J.P., Palmerini F., Dubreuil P., Moussy A., Hermine O.: Masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med 2008, 22, 1301–1309, doi: 10.1111/j.1939-1676.2008.0190.x. Hahn K.A. Oglivie G. Rusk T. Devauchelle P. Leblanc A. Legendre A. Powers B. Leventhal P.S. Kinet J.P. Palmerini F. Dubreuil P. Moussy A. Hermine O. Masitinib is safe and effective for the treatment of canine mast cell tumors J Vet Intern Med 2008 22 1301 1309 10.1111/j.1939-1676.2008.0190.x18823406Open DOISearch in Google Scholar

8Holtermann N., Kiupel M., Kessler M., Teske E., Betz D., Hirschberger J.: Masitinib monotherapy in canine epitheliotropic lymphoma. Vet Comp Oncol 2016, 14, 127–135, doi: 10.1111/ vco.12157. Holtermann N. Kiupel M. Kessler M. Teske E. Betz D. Hirschberger J. Masitinib monotherapy in canine epitheliotropic lymphoma Vet Comp Oncol 2016 14 127 135 10.1111/vco.1215726364581Open DOISearch in Google Scholar

9Karayannopoulou M., Lafioniatis S.: Recent advances on canine mammary cancer chemotherapy: A review of studies from 2000 to date. Revue Méd Vét 2016, 167, 192–200. Karayannopoulou M. Lafioniatis S. Recent advances on canine mammary cancer chemotherapy: A review of studies from 2000 to date Revue Méd Vét 2016 167 192 200Search in Google Scholar

10Kaszak I., Ruszczak A., Kanafa S., Kacprzak K., Król M., Jurka P.: Current biomarkers of canine mammary tumors. Acta Vet Scand 2018, 60, 66, doi: 10.1186/s13028-018-0417-1. Kaszak I. Ruszczak A. Kanafa S. Kacprzak K. Król M. Jurka P. Current biomarkers of canine mammary tumors Acta Vet Scand 2018 60 66 10.1186/s13028-018-0417-1620670430373614Open DOISearch in Google Scholar

11Kato Y., Asano K., Mogi T., Kutara K., Teshima K., Edamura K., Tsumagari S., Hasegawa A., Tanaka S.: Clinical significance of circulating vascular endothelial growth factor in dogs with mammary gland tumors. J Vet Med Sci 2007, 69, 77–80, doi: 10.1292/jvms.69.77. Kato Y. Asano K. Mogi T. Kutara K. Teshima K. Edamura K. Tsumagari S. Hasegawa A. Tanaka S. Clinical significance of circulating vascular endothelial growth factor in dogs with mammary gland tumors J Vet Med Sci 2007 69 77 80 10.1292/jvms.69.7717283406Open DOISearch in Google Scholar

12Koltai Z., Szabó B., Jakus J., Vajdovich P.: Tyrosine kinase expression analyses in canine mammary gland tumours – A pilot study. Acta Vet Hung 2018, 66, 294–308, doi: 10.1556/004.2018.027. Koltai Z. Szabó B. Jakus J. Vajdovich P. Tyrosine kinase expression analyses in canine mammary gland tumours – A pilot study Acta Vet Hung 2018 66 294 308 10.1556/004.2018.02729958529Open DOISearch in Google Scholar

13Kubo K., Matsuyama S., Katayama K., Tsutsumi C., Yonezawa K., Shimada T., Kotani T., Sakuma S., Ohashi F., Takamori Y.: Frequent expression of the c-kit proto-oncogene in canine malignant mammary tumor. J Vet Med Sci 1998, 60, 1335–1340, doi: 10.1292/jvms.60.1335. Kubo K. Matsuyama S. Katayama K. Tsutsumi C. Yonezawa K. Shimada T. Kotani T. Sakuma S. Ohashi F. Takamori Y. Frequent expression of the c-kit proto-oncogene in canine malignant mammary tumor J Vet Med Sci 1998 60 1335 1340 10.1292/jvms.60.13359879535Open DOISearch in Google Scholar

14Lawrence J., Saba C., Gogal Jr R., Lamberth O., Vandenplas M.L., Hurley D.J., Dubreuil P., Hermine O., Dobbin K., Turek M.: Masitinib demonstrates anti‐proliferative and pro‐apoptotic activity in primary and metastatic feline injection‐site sarcoma cells. Vet Comp Oncol 2012, 10, 143–154, doi: 10.1111/j.1476-5829.2011.00291.x. Lawrence J. Saba C. Gogal Jr R. Lamberth O. Vandenplas M.L. Hurley D.J. Dubreuil P. Hermine O. Dobbin K. Turek M. Masitinib demonstrates anti‐proliferative and pro‐apoptotic activity in primary and metastatic feline injection‐site sarcoma cells Vet Comp Oncol 2012 10 143 154 10.1111/j.1476-5829.2011.00291.x22236016Open DOISearch in Google Scholar

15Lyles S.E., Milner R.J., Kow K., Salute M.E.: In vitro effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine hemangiosarcoma cell lines. Vet Comp Oncol 2012, 10, 223–235, doi: 10.1111/j.1476-5829.2012.00335.x. Lyles S.E. Milner R.J. Kow K. Salute M.E. In vitro effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine hemangiosarcoma cell lines Vet Comp Oncol 2012 10 223 235 10.1111/j.1476-5829.2012.00335.x22594682Open DOISearch in Google Scholar

16Marech I., Patruno R., Zizzo N., Gadaleta C., Introna M., Zito A.F., Gadaleta C.D., Ranieri G.: Masitinib (AB1010), from canine tumor model to human clinical development: where we are? Crit Rev Oncol Hematol 2014, 91, 98–111, doi: 10.1016/j.critrevonc.2013.12.011. Marech I. Patruno R. Zizzo N. Gadaleta C. Introna M. Zito A.F. Gadaleta C.D. Ranieri G. Masitinib (AB1010), from canine tumor model to human clinical development: where we are? Crit Rev Oncol Hematol 2014 91 98 111 10.1016/j.critrevonc.2013.12.01124405856Open DOISearch in Google Scholar

17Michishita M., Ohtsuka A., Nakahira R., Tajima T., Nakagawa T., Sasaki N., Arai T., Takahashi K.: Anti-tumor effect of bevacizumab on a xenograft model of feline mammary carcinoma. J Vet Med Sci 2016, 78, 685–694, doi: 10.1292/jvms.15-0550. Michishita M. Ohtsuka A. Nakahira R. Tajima T. Nakagawa T. Sasaki N. Arai T. Takahashi K. Anti-tumor effect of bevacizumab on a xenograft model of feline mammary carcinoma J Vet Med Sci 2016 78 685 694 10.1292/jvms.15-0550487386226616000Open DOISearch in Google Scholar

18Milovancev M., Helfand S.C., Marley K., Goodall C.P., Löhr C.V., Bracha S.: Antiproliferative effects of masitinib and imatinib against canine oral fibrosarcoma in vitro. BMC Vet Res 2016, 12, 85, doi: 10.1186/s12917-016-0712-x. Milovancev M. Helfand S.C. Marley K. Goodall C.P. Löhr C.V. Bracha S. Antiproliferative effects of masitinib and imatinib against canine oral fibrosarcoma in vitro BMC Vet Res 2016 12 85 10.1186/s12917-016-0712-x489327927259510Open DOISearch in Google Scholar

19Pena L.L., Nieto A.I., Pérez-Alenza D., Cuesta P., Castano M.: Immunohistochemical detection of Ki-67 and PCNA in canine mammary tumors: relationship to clinical and pathologic variables. J Vet Diagn Invest 1998, 10, 237–246, doi: 10.1177/104063879801000303. Pena L.L. Nieto A.I. Pérez-Alenza D. Cuesta P. Castano M. Immunohistochemical detection of Ki-67 and PCNA in canine mammary tumors: relationship to clinical and pathologic variables J Vet Diagn Invest 1998 10 237 246 10.1177/1040638798010003039683072Open DOISearch in Google Scholar

20Queiroga F.L., Raposo T., Carvalho M.I., Prada J., Pires I.: Canine mammary tumours as a model to study human breast cancer: most recent findings. In Vivo 2011, 25, 455–465. Queiroga F.L. Raposo T. Carvalho M.I. Prada J. Pires I. Canine mammary tumours as a model to study human breast cancer: most recent findings In Vivo 2011 25 455 465Search in Google Scholar

21Ranieri G., Gadaleta C.D., Patruno R., Zizzo N., Daidone M.G., Hansson M.G., Paradiso A., Ribatti D.: A model of study for human cancer: Spontaneous occurring tumors in dogs. Biological features and translation for new anticancer therapies. Crit Rev Oncol Hematol 2013, 88, 187–197, doi: 10.1016/j.critrevonc.2013.03.005. Ranieri G. Gadaleta C.D. Patruno R. Zizzo N. Daidone M.G. Hansson M.G. Paradiso A. Ribatti D. A model of study for human cancer: Spontaneous occurring tumors in dogs Biological features and translation for new anticancer therapies. Crit Rev Oncol Hematol 2013 88 187 197 10.1016/j.critrevonc.2013.03.00523561333Open DOISearch in Google Scholar

22Restucci B., Papparella S., Maiolino P., De Vico G.: Expression of vascular endothelial growth factor in canine mammary tumors. Vet Pathol 2002, 39, 488–493, doi: 10.1354/vp.39-4-488. Restucci B. Papparella S. Maiolino P. De Vico G. Expression of vascular endothelial growth factor in canine mammary tumors Vet Pathol 2002 39 488 493 10.1354/vp.39-4-48812126152Open DOISearch in Google Scholar

23Sandström M., Johansson M., Andersson U., Bergh A., Bergenheim A.T., Henriksson R.: The tyrosine kinase inhibitor ZD6474 inhibits tumour growth in an intracerebral rat glioma model. Br J Cancer 2004, 91, 1174–1180, doi: 10.1038/sj.bjc.6602108. Sandström M. Johansson M. Andersson U. Bergh A. Bergenheim A.T. Henriksson R. The tyrosine kinase inhibitor ZD6474 inhibits tumour growth in an intracerebral rat glioma model Br J Cancer 2004 91 1174 1180 10.1038/sj.bjc.6602108274768815305185Open DOISearch in Google Scholar

24Scholzen T., Gerdes J.: The Ki‐67 protein: from the known and the unknown. J Cell Physiol 2000, 182, 311–322, doi: 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9. Scholzen T. Gerdes J. The Ki‐67 protein: from the known and the unknown J Cell Physiol 2000 182 311 322 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9Open DOISearch in Google Scholar

25Stabile L.P., Lyker J.S., Gubish C.T., Zhang W., Grandis J.R., Siegfried J.M.: Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non–small cell lung cancer shows enhanced antiproliferative effects. Cancer Res 2005, 65, 1459–1470, doi: 10.1158/0008-5472.CAN-04-1872. Stabile L.P. Lyker J.S. Gubish C.T. Zhang W. Grandis J.R. Siegfried J.M. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non–small cell lung cancer shows enhanced antiproliferative effects Cancer Res 2005 65 1459 1470 10.1158/0008-5472.CAN-04-1872Open DOISearch in Google Scholar

26Thamm D.H., Rose B., Kow K., Humbert M., Mansfield C.D., Moussy A., Hermine O., Dubreuil P.: Masitinib as a chemosensitizer of canine tumor cell lines: a proof of concept study. Vet J 2012, 191, 131–134, doi: 10.1016/j.tvjl.2011.01.001. Thamm D.H. Rose B. Kow K. Humbert M. Mansfield C.D. Moussy A. Hermine O. Dubreuil P. Masitinib as a chemosensitizer of canine tumor cell lines: a proof of concept study Vet J 2012 191 131 134 10.1016/j.tvjl.2011.01.001Open DOISearch in Google Scholar

27Wilhelm S.M., Adnane L., Newell P., Villanueva A., Llovet J.M., Lynch M.: Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008, 7, 3129–3140, doi: 10.1158/1535-7163.MCT-08-0013. Wilhelm S.M. Adnane L. Newell P. Villanueva A. Llovet J.M. Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling Mol Cancer Ther 2008 7 3129 3140 10.1158/1535-7163.MCT-08-0013Open DOISearch in Google Scholar

28Wolfesberger B., Tonar Z., Gerner W., Skalicky M., Heiduschka G., Egerbacher M., Thalhammer J.G., Walter I.: The tyrosine kinase inhibitor sorafenib decreases cell number and induces apoptosis in a canine osteosarcoma cell line. Res Vet Sci 2010, 88, 94–100, doi: 10.1016/j.rvsc.2009.06.009. Wolfesberger B. Tonar Z. Gerner W. Skalicky M. Heiduschka G. Egerbacher M. Thalhammer J.G. Walter I. The tyrosine kinase inhibitor sorafenib decreases cell number and induces apoptosis in a canine osteosarcoma cell line Res Vet Sci 2010 88 94 100 10.1016/j.rvsc.2009.06.009Open DOISearch in Google Scholar

29Xiao X., Wu J., Zhu X., Zhao P., Zhou J., Liu Q.Q., Zheng L., Zeng M., Liu R., Huang W.: Induction of cell cycle arrest and apoptosis in human nasopharyngeal carcinoma cells by ZD6474, an inhibitor of VEGFR tyrosine kinase with additional activity against EGFR tyrosine kinase. Int J Cancer 2007, 121, 2095–2104, doi: 10.1002/ijc.22955. Xiao X. Wu J. Zhu X. Zhao P. Zhou J. Liu Q.Q. Zheng L. Zeng M. Liu R. Huang W. Induction of cell cycle arrest and apoptosis in human nasopharyngeal carcinoma cells by ZD6474, an inhibitor of VEGFR tyrosine kinase with additional activity against EGFR tyrosine kinase Int J Cancer 2007 121 2095 2104 10.1002/ijc.22955Open DOISearch in Google Scholar

30Zhou X., Zheng M., Chen F., Zhu Y., Yong W., Lin H., Sun Y., Han X.: Gefitinib inhibits the proliferation of pancreatic cancer cells via cell cycle arrest. Anat Rec (Hoboken) 2009, 292, 1122–1127, doi: 10.1002/ar.20938. Zhou X. Zheng M. Chen F. Zhu Y. Yong W. Lin H. Sun Y. Han X. Gefitinib inhibits the proliferation of pancreatic cancer cells via cell cycle arrest Anat Rec (Hoboken) 2009 292 1122 1127 10.1002/ar.20938Open DOISearch in Google Scholar